Impact of Valve Culture Positivity on Prognosis in Patients with Infective Endocarditis Who Underwent Valve Surgery

Jinnam Kim · Jung Ho Kim · Hi Jae Lee · Se Ju Lee · Ki Hyun Lee · Eun Hwa Lee · Yae Jee Baek · Jin Young Ahn · Su Jin Jeong · Nam Su Ku · Seung Hyun Lee · Jun Yong Choi · Joon-Sup Yeom

Received: March 10, 2022 / Accepted: April 11, 2022 / Published online: April 30, 2022 © The Author(s) 2022

ABSTRACT

Introduction: Infective endocarditis (IE) is a severe and fatal infection with high in-hospital and overall mortality rates of approximately up to 30%. Valve culture positivity was associated with in-hospital mortality and postoperative complications; however, few studies have analyzed the relationship between valve cultures and overall mortality over a long observation period. This study aimed to compare the association of valve culture positivity with overall mortality in patients with IE who underwent valve surgery.

Methods: A total of 416 IE patients admitted to a tertiary hospital in South Korea from November 2005 to August 2017 were retrospectively reviewed. A total of 202 IE patients who underwent valve surgery and valve culture were enrolled. The primary endpoint was long-term overall mortality. Kaplan–Meier curve and Cox proportional hazards model were used for survival analysis.

Results: The median follow-up duration was 63 (interquartile range, 38–104) months. Valve cultures were positive in 22 (10.9%) patients. The overall mortality rate was 15.8% (32/202) and was significantly higher in valve culture-positive patients (36.4%, \( p = 0.011 \)). Positive valve culture [hazard ratio (HR) 3.921, \( p = 0.002 \)], Charlson Comorbidity Index (HR 1.181, \( p = 0.004 \)), Coagulase-negative staphylococci (HR 4.233, \( p = 0.001 \)), new-onset central nervous system complications (HR 3.689, \( p < 0.001 \)), and new-onset heart failure (HR 4.331, \( p = 0.001 \)) were significant risk factors for overall mortality.

Conclusions: Valve culture positivity is a significant risk factor for long-term overall mortality in IE patients who underwent valve surgery. The importance of valve culture

Jinnam Kim and Jung Ho Kim contributed equally to this study.

J. Kim · J. H. Kim · S. J. Lee · K. H. Lee · E. H. Lee · Y. J. Baek · J. Y. Ahn · S. J. Jeong · N. S. Ku (✉) · J. Y. Choi · J.-S. Yeom
Division of Infectious Disease, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea
e-mail: smileboy9@yuhs.ac

J. Kim · J. H. Kim · S. J. Lee · K. H. Lee · E. H. Lee · Y. J. Baek · J. Y. Ahn · S. J. Jeong · N. S. Ku · J. Y. Choi · J.-S. Yeom
AIDS Research Institute, Yonsei University College of Medicine, Seoul, Korea

H. J. Lee · S. H. Lee (✉)
Department of Cardiovascular Surgery, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea
e-mail: henry75@yuhs.ac

N. S. Ku
Department of Internal Medicine, AIDS Research Institute, Severance Hospital, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea
positivity needs to be re-evaluated, as the valve culture positivity rate increases with increasing early surgical intervention.

**Keywords:** Endocarditis; Heart valves; Mortality; Tissue culture

### Key Summary Points

- Infective endocarditis (IE) is still associated with high mortality rates
- The association of valve culture positivity with long-term mortality is unclear
- Positive valve culture is related to local infection and systemic infection burden
- Positive valve culture increases long-term mortality in IE patients with surgery

### INTRODUCTION

Infective endocarditis (IE) is a severe and potentially fatal infection with high in-hospital and overall mortality rates of approximately 10–20% and up to 30%, respectively, despite appropriate antibiotic treatment and improved surgical interventions [1–3]. Advanced age, structural heart disease, prosthetic valve, intravascular catheter, and prior IE are well-known risk factors for IE [4]. Patients with prosthetic valves and previous episodes of IE are at the highest risk and require antibiotic prophylaxis [5].

Several prognostic factors for increased mortality have been identified, including host factors, pathogen-specific factors, and treatment-related factors. Age, comorbidities, and a history of IE have also been associated with IE mortality [6–8]. Surgical intervention is important to reduce complications and mortality, and is recommended in about half of all IE patients [9, 10]. However, even with surgical intervention, the overall mortality is still approximately 10–17% [11].

In addition, positive tissue valve culture has been associated with in-hospital mortality and postoperative complications [12–14]. Valve culture is an independent predictor of in-hospital mortality in active left-sided IE [12]. Therefore, the European Society of Cardiology (ESC) guideline recommends that positive valve culture should guide antibiotic choice and treatment duration [13]. Positive valve culture also increases the risk of postoperative complications, such as acute respiratory distress syndrome (ARDS) and paravalvular leakage [13, 14]. However, few studies have analyzed the relationship between valve cultures and overall mortality over a long observation period.

This study aimed to compare the difference in long-term overall mortality according to valve culture results in IE patients who underwent surgical intervention.

### METHODS

**Patient Selection**

We retrospectively reviewed 416 IE patients admitted to Severance Hospital, a 2400-bed tertiary hospital in South Korea, from November 2005 to August 2017. We defined IE according to the modified Duke criteria, and included cases of “definite IE” and “possible IE” [15]. Eligibility criteria were as follows: age > 18 years, valve surgery, and appropriate valve culture. Patients who received a prolonged course of antibiotics after surgery, such as those with tuberculosis or fungal infection, were excluded from this study (n = 2). We also excluded cases in which valve culture was not performed or only a swab culture at the surgical site was performed (n = 43) [16]. In cases of multiple episodes in the same patient, only data from the first episode were analyzed, and subsequent events were described as recurrence. This study was approved by the institutional review boards (IRBs) of Yonsei University College of Medicine (IRB no. 4-2018-0248). Informed consent was waived due to the retrospective nature of the study, which complied with the Good Clinical Practice guidelines and the Declaration of Helsinki.
Definition of Variables

Antibiotics were selected according to the ESC guidelines [5]. The duration of antibiotic treatment was considered when one of the compounds was effective against the causative microorganism, and when the antibiotic was administered intravenously; specifically, if one of the empirically started antibiotics was susceptible to the identified strain, this was counted from the first entry date, whereas if no empirically started antibiotic was susceptible to the identified strain, this was counted from the date of change according to susceptibility [17]. Surgical intervention was recommended, based on a multidisciplinary team decision according to the American Heart Association and ESC guidelines [5, 18]. Appropriate valve culture was performed using aseptically removed valve specimens during surgery [19]. Causative microorganisms were defined as pathogens cultured from blood or tissue samples [20]. Reoperation was defined as a case requiring additional surgery on the same heart valve for the treatment of IE recurrence or postoperative valve complications [21]. The Charlson Comorbidity Index was used to estimate the risk of death from comorbidities present on admission [22]. The European System for Cardiac Operative Risk Evaluation II (EuroSCORE) is used for surgical risk stratification in IE patients [23]. The mortality data were obtained from the Ministry of the Interior and Safety of South Korea, which collects mortality data of all Korean citizens. The primary endpoint of this study was overall mortality during the observational period. Overall mortality was defined as death from any cause. The secondary endpoints were in-hospital mortality, 1-year mortality, 1-year reoperation, overall reoperation, and postoperative complications, such as new-onset heart failure (HF), conduction abnormality, and paravalvular and embolic complications.

Statistical Analysis

Between-group comparison was performed using the chi-squared and Fisher’s exact tests for categorical variables and the Mann–Whitney U test for continuous variables. A p-value of < 0.05 was considered statistically significant. A Kaplan–Meier curve was drawn using patient survival from the time of admission to either death or date of the last follow-up. The log-rank test was used to determine whether there was a difference in survival distributions between the two groups. Hazard ratios (HRs) and 95% confidence intervals (CIs) of variables for overall mortality were analyzed using a Cox proportional hazards model. Variables for multivariable analysis were selected based on the clinically significant risk factors in univariable analysis. Statistical analysis was performed using IBM SPSS Statistics for Windows v.25 (IBM, Armonk, NY, USA).

RESULTS

Patient Characteristics

Of 416 IE patients in total, 247 patients who underwent valve surgery were enrolled (Fig. 1). Of 247 patients, only 81.8% underwent appropriate valve culture. The valve culture results were positive in 10.9% and negative in 89.1% of patients. The median age of the study population was 53 [interquartile range (IQR), 39–65] years, and 65.3% of patients were male (Table 1). The most affected valves were the mitral valve (64.9%) and aortic valve (48.5%). Multiple valve involvement occurred in 19% of patients. Approximately 40.1% of patients had a previous history of valve dysfunction, including prosthetic valve (10.9%), previous valve surgery (14.9%), cardiac devices (2.5%), and other structural problems, such as rheumatic heart disease, mitral valve prolapse, and bicuspid aortic valve. The most frequently isolated microorganisms were streptococci (40.1%), followed by coagulase-negative staphylococci (CoNS) (8.4%), and Staphylococcus aureus (7.9%). Sixty-one patients (30.2%) had negative blood culture results. There were no differences in sex, IE history, history of valve dysfunction, affected valves, comorbidities, microorganisms, duration of total antibiotic treatment, and vegetation size between patients with positive and negative valve culture results. However, patients
with positive valve culture results had a higher rate of left ventricular dysfunction (63.6% vs. 36.1%, \( p = 0.013 \)), were older [62 (IQR, 45–72) vs. 52 (IQR, 38–63), \( p = 0.033 \)], had a higher Charlson Comorbidity Index [3 (IQR, 0–5) vs. 1 (IQR, 0–3), \( p = 0.035 \)], and a higher EuroSCORE value [2.70 (IQR, 2.07–4.20) vs. 2.06 (IQR, 1.53–2.82), \( p = 0.003 \)] than patients with negative valve culture results.

### Outcomes According to Valve Culture Results

The median follow-up duration was 63 (IQR, 38–104) months. The 1-year mortality rate (31.8% vs. 8.9%, \( p = 0.005 \)) and overall mortality rate (36.4% vs. 12.9%, \( p = 0.011 \)) were significantly higher in IE patients with positive valve cultures (Table 2). This significant difference in overall mortality between patients with positive and negative valve cultures was confirmed by the Kaplan–Meier curve and log-rank test \( p = 0.002 \) (Fig. 2). In-hospital mortality tended to be higher in valve culture-positive patients than in valve culture-negative patients; nevertheless, this difference was not statistically significant (18.2% vs. 6.1%, \( p = 0.064 \)) (Table 2).

No statistically significant difference in complications was identified between the valve culture-positive and -negative groups, as follows: new-onset HF (13.6% vs. 13.3%, \( p = 0.999 \)), new conduction abnormality (9.1% vs. 8.9%, \( p = 0.999 \)), paravalvular complications (22.7% vs. 13.9%, \( p = 0.336 \)), CNS embolic events (36.4% vs. 30.6%, \( p = 0.579 \)), renal failure (18.2% vs. 10.0%, \( p = 0.271 \)), peripheral arterial occlusive disease (4.5% vs. 1.1%,
Table 1 Baseline characteristics of infective endocarditis patients who underwent valve surgery

|                         | Total (n = 202) | Valve culture | p value |
|-------------------------|----------------|---------------|---------|
|                         |                | Negative (n = 180, 89.1%) | Positive (n = 22, 10.9%) |
| Age (years)             | 53 (39–65)     | 52 (38–63)    | 62 (45–72) | 0.033 |
| Male sex                | 132 (65.3%)    | 118 (65.6%)   | 14 (63.6%) | 0.858 |
| Nosocomial infection    | 22 (10.9%)     | 19 (10.6%)    | 3 (13.6%)  | 0.715 |
| Previous IE             | 6 (3.0%)       | 6 (3.3%)      | 0 (0.0%)   | 0.999 |
| Underlying cardiac valve conditions | 81 (40.1%) | 72 (40.0%) | 9 (40.9%) | 0.935 |
| Prosthetic valve        | 22 (10.9%)     | 19 (10.6%)    | 3 (13.6%)  | 0.715 |
| Previous valve surgery  | 30 (14.9%)     | 25 (13.9%)    | 5 (22.7%)  | 0.336 |
| Cardiac devices         | 5 (2.5%)       | 3 (1.7%)      | 2 (9.1%)   | 0.093 |
| Affected valve          |                |               |          |
| Aortic valve            | 98 (48.5%)     | 87 (48.3%)    | 11 (50.0%) | 0.883 |
| Mitral valve            | 131 (64.9%)    | 118 (65.6%)   | 13 (59.1%) | 0.549 |
| Tricuspid valve         | 10 (5.0%)      | 7 (3.9%)      | 3 (13.6%)  | 0.081 |
| Pulmonary valve         | 6 (3.0%)       | 5 (2.8%)      | 1 (4.5%)   | 0.504 |
| Multiple valves         | 39 (19.3%)     | 34 (18.9%)    | 5 (22.7%)  | 0.774 |
| Other comorbidities     |                |               |          |
| Diabetes mellitus       | 30 (14.9%)     | 24 (13.3%)    | 6 (27.3%)  | 0.107 |
| Chronic heart failure   | 12 (5.9%)      | 10 (5.6%)     | 2 (9.1%)   | 0.624 |
| Renal disease           | 13 (6.4%)      | 10 (5.6%)     | 3 (13.6%)  | 0.156 |
| Liver disease           | 9 (4.5%)       | 8 (4.4%)      | 1 (4.5%)   | 0.999 |
| Solid cancer            | 13 (6.4%)      | 11 (6.1%)     | 2 (9.1%)   | 0.638 |
| Hematologic malignancy  | 1 (0.5%)       | 1 (0.6%)      | 0 (0.0%)   | 0.999 |
| Connective tissue disease | 7 (3.5%)  | 6 (3.3%) | 1 (4.5%) | 0.560 |
| Immunosuppressive therapy | 5 (2.5%) | 5 (2.8%) | 0 (0.0%) | 0.999 |
| Table 1 continued | Total \((n = 202)\) | Valve culture | \(p\) value |
|------------------|-------------------|---------------|-------------|
|                  |                   | Negative \((n = 180, 89.1\%)\) | Positive \((n = 22, 10.9\%)\) |
| Antibiotic treatment within 30 days | 25 (12.4\%) | 21 (11.7\%) | 4 (18.2\%) | 0.488 |
| Central venous access | 6 (3.0\%) | 4 (2.2\%) | 2 (9.1\%) | 0.13 |
| Charlson Comorbidity Index | 1 (0–3) | 1 (0–3) | 3 (0–5) | 0.035 |
| EuroSCORE value (median, IQR) | 2.08 (1.53–2.86) | 2.06 (1.53–2.82) | 2.70 (2.07–4.20) | 0.003 |
| Clinical signs and symptoms (initial) | | | |
| Fever \((\geq 38 \degree C)\) | 144 (71.3\%) | 128 (71.1\%) | 16 (72.7\%) | 0.874 |
| LV dysfunction \((EF < 50\%)\) | 79 (39.1\%) | 65 (36.1\%) | 14 (63.6\%) | 0.013 |
| Sepsis (including septic shock) | 131 (64.9\%) | 114 (63.3\%) | 17 (77.3\%) | 0.196 |
| CNS embolic complications | 65 (32.2\%) | 56 (31.1\%) | 9 (40.9\%) | 0.353 |
| Peripheral embolic complications | 18 (8.9\%) | 16 (8.9\%) | 2 (9.1\%) | 0.999 |
| Skin lesions | 4 (2.0\%) | 4 (2.2\%) | 0 (0.0\%) | 0.999 |
| Microbiology | | | |
| Coagulase-negative staphylococci | 17 (8.4\%) | 14 (7.8\%) | 3 (13.6\%) | 0.406 |
| *Staphylococcus aureus* | 16 (7.9\%) | 13 (7.2\%) | 3 (13.6\%) | 0.392 |
| MSSA | 12 (5.9\%) | 11 (6.1\%) | 1 (4.5\%) | 0.999 |
| MRSA | 4 (2.0\%) | 2 (1.1\%) | 2 (9.1\%) | 0.059 |
| *Enterococcus* species | 16 (7.9\%) | 13 (7.2\%) | 3 (13.6\%) | 0.392 |
| *Streptococcus* species | 81 (40.1\%) | 73 (40.6\%) | 8 (36.4\%) | 0.705 |
| HACEK | 2 (1.0\%) | 1 (0.6\%) | 1 (4.5\%) | 0.206 |
| Gram-negative bacilli (except for HACEK) | 1 (0.5\%) | 1 (0.6\%) | 0 (0.0\%) | 0.999 |
| Others | 8 (4.0\%) | 7 (3.9\%) | 1 (4.5\%) | 0.999 |
| Duration of total antibiotic treatment | 33 (27–42) | 32 (27–41) | 38 (28–47) | 0.248 |
| Duration of presoperative antibiotic treatment | 10 (5–19) | 9 (5–17) | 5 (2–16) | 0.479 |
Univariable and Multivariable Analyses of Overall Mortality

Univariable analysis showed that Charlson Comorbidity Index ($p = 0.01$), positive valve culture ($p = 0.001$), new-onset central nervous system (CNS) complications ($p < 0.001$), and new-onset HF ($p = 0.002$) were associated with an increase in overall mortality (Table 3).

In the multivariable model, Charlson Comorbidity Index ($p = 0.004$), CoNS ($p = 0.001$), positive valve culture ($p = 0.002$), new-onset CNS complications ($p < 0.001$), and new-onset HF ($p = 0.001$) had a significant impact on increasing overall mortality (Table 3).

DISCUSSION

Our study showed that positive valve culture increased the risk of overall mortality in IE patients who underwent valve surgery over a long-term follow-up period, and revealed that new-onset CNS complications, new-onset HF, and Charlson Comorbidity Index were significant predictive factors influencing long-term overall mortality.

Numerous studies have evaluated predictors of poor outcomes and mortality in IE patients. HF and neurological complications are independent predictive factors for mortality in IE patients who underwent surgery [6–8, 24]. Several models included predictive factors that can affect mortality, such as prior cardiac surgery, number of treated valves/prostheses, left ventricular ejection fraction, comorbidities, and microorganisms [25, 26]. Our study showed that positive valve culture was a significant risk factor for overall mortality over a long-term follow-up period.

Positive valve culture is required for the diagnosis of “definite” IE according to the modified Duke criteria [15]. Positive valve culture is also a crucial factor influencing antibiotic choice and duration of treatment after surgical intervention (Class IIa; Level of Evidence B).
A previous study suggested that the duration of antibiotic treatment and vegetation size were independent predictive factors for positive valve culture [13]. Data from a randomized controlled trial and large meta-analysis support early surgical intervention in IE [10, 27]. Early surgical intervention reduced the risk of HF and emboli, but increased the proportion of positive valve cultures [13]. A positive valve culture result could be due to a higher grade of bacteremia, insufficient therapeutic time, or antibiotic treatment failure [12]. Further, positive valve culture was indicative of active local infection in IE patients undergoing cardiac surgery [12].

In addition, positive valve culture was associated with poor clinical outcomes in IE patients who underwent surgery; for example, positive valve culture increased the risk of postoperative ARDS and paravalvular leakage [13, 14], and was associated with higher in-hospital mortality rates [12]. Our study showed no difference in paravalvular leakage or other complications according to the valve culture results, but 1-year mortality (31.8% vs. 8.9%, \( p = 0.005 \)) and overall mortality (36.4% vs. 12.9%, \( p = 0.011 \)) were significantly higher in patients with positive valve cultures compared to those with negative valve cultures. Thus, positive valve culture is an important determinant of IE diagnosis and treatment, and is also associated with the duration of appropriate antibiotic treatment, vegetation size, postoperative complications, and mortality.

CoNS is an important causative pathogen in prosthetic valve endocarditis (PVE) and native valve endocarditis (NVE). CoNS invades and destroys native tissue and forms biofilms by binding with polymer surfaces of foreign bodies [28, 29]. Some studies have found that CoNS increases the risk of in-hospital mortality and relapse in patients with PVE [30, 31]. NVE

### Table 2 Postoperative outcomes of patients with infective endocarditis after valve surgery

| Postoperative outcomes | Total (\( n = 202 \)) | Valve culture | \( p \) value |
|------------------------|------------------------|---------------|--------------|
|                        | Negative (\( n = 180, 89.1\%) | Positive (\( n = 22, 10.9\% \)) |
| In-hospital mortality  | 15 (7.4%)              | 11 (6.1%)     | 4 (18.2%)    | 0.064 |
| 1-year mortality       | 23 (11.4%)             | 16 (8.9%)     | 7 (31.8%)    | 0.005 |
| Overall mortality      | 32 (15.8%)             | 24 (12.9%)    | 8 (36.4%)    | 0.011 |
| New-onset heart failure| 27 (13.4%)             | 24 (13.3%)    | 3 (13.6%)    | 0.999 |
| New conduction abnormality | 18 (8.9%)           | 16 (8.9%)     | 2 (9.1%)     | 0.999 |
| Paravalvular complications | 30 (14.9%)         | 25 (13.9%)    | 5 (22.7%)    | 0.336 |
| Embolic complications  |                        |               |              |
| CNS involvement        | 63 (31.2%)             | 55 (30.6%)    | 8 (36.4%)    | 0.579 |
| Renal failure          | 22 (10.9%)             | 18 (10%)      | 4 (18.2%)    | 0.271 |
| PAOD                   | 3 (1.5%)               | 2 (1.1%)      | 1 (4.5%)     | 0.294 |
| Other systemic emboli  | 18 (8.9%)              | 16 (8.9%)     | 2 (9.1%)     | 0.999 |
| 1-year reoperation\(^a\) | 5 (2.5%)               | 4 (2.2%)      | 1 (4.5%)     | 0.442 |
| Overall reoperation\(^a\) | 7 (3.5%)               | 7 (3.9%)      | 1 (4.5%)     | 0.999 |

\( CNS \) central nervous system; \( PAOD \) peripheral arterial occlusive disease

\(^a\)Reoperation: a case requiring additional surgery on the same heart valve, not only for the recurrence of infective endocarditis but also for postoperative valve complications.
caused by CoNS was also associated with poor outcomes and high overall mortality, despite the high rate of surgical procedures [32]. In our study, CoNS infection was also a significant risk factor associated with overall mortality.

IE leads to HF by destroying structures important to hemodynamics through multiple mechanisms including vegetations, destructive valve lesions, and abscess formation [33]. HF is the most frequent complication, affecting up to 60% of IE patients, and is also the main cause of death in IE patients [6]. HF is also the most common indication for surgical intervention in IE, and early surgery is associated with reduced mortality [9]. Of note, HF remained an independent predictor of in-hospital and 1-year mortality in IE patients, despite appropriate surgical intervention [6, 7]. Several studies have shown that HF is also the main cause of long-term mortality in IE patients [34, 35]. These findings are consistent with our own observations showing that HF was a significant risk factor for long-term overall mortality.

CNS complications occur in up to 30% of IE patients, and are the result of emboli, which are related to vegetation length and mobility

### Table 3: Univariable and multivariable analyses of overall mortality in patients with infective endocarditis using a Cox proportional hazards model

| Characteristics                        | n   | Univariable analysis |             |             | Multivariable analysis |             |
|----------------------------------------|-----|----------------------|-------------|-------------|------------------------|-------------|
|                                        |     | HR 95% CI p-value    | HR 95% CI p-value |
| Sex                                    |     |                      |              |              |                        |              |
| Male                                   | 132 | 1                    |              |              |                        |              |
| Female                                 | 70  | 0.605 0.255–1.439 0.256 |              |              |                        |              |
| Multiple valve involvement             | 39  | 0.731 0.270–1.979 0.538 |              |              |                        |              |
| Previous infective endocarditis        | 6   | 1.029 0.118–8.985 0.979 |              |              |                        |              |
| Previous valve problem historya        | 81  | 2.029 0.880–4.679 0.097 |              |              |                        |              |
| Charlson Comorbidity Index             |     | 1.177 1.040–1.331 0.01 | 1.181 1.054–1.324 0.004 |              |                        |              |
| Microbiology                            |     |                      |              |              |                        |              |
| CoNS                                   | 17  | 5.208 0.836–32.444 0.077 | 4.233 1.788–10.023 0.001 |              |                        |              |
| S. aureus                              | 16  | 1.308 0.176–9.705 0.793 |              |              |                        |              |
| Enterococcus                           | 16  | 0.898 0.095–8.487 0.925 |              |              |                        |              |
| Streptococcus                          | 81  | 0.728 0.127–4.167 0.722 |              |              |                        |              |
| Blood culture-negative                  | 61  | 1.817 0.268–12.325 0.541 |              |              |                        |              |
| Valve culture                           |     |                      |              |              |                        |              |
| Negative                               | 180 | 1                    |              |              |                        |              |
| Positive                               | 22  | 5.608 2.071–15.188 < 0.001 | 3.921 1.681–9.145 0.002 |              |                        |              |
| New-onset CNS complications             | 63  | 4.166 1.883–9.217 < 0.001 | 3.689 1.783–7.633 < 0.001 |              |                        |              |
| New-onset HF                           | 27  | 4.214 1.671–10.628 0.002 | 4.331 1.839–10.196 0.001 |              |                        |              |

HR hazard ratio; CI confidence interval; CoNS coagulase-negative staphylococci; S. aureus, Staphylococcus aureus; CNS central nervous system; HF heart failure

aPrevious valve problem history: prosthetic valve, previous valve surgery, cardiac devices, rheumatic heart disease, mitral valve prolapse, bicuspid aortic valves, and other valve structural causes
Initiating appropriate antibiotic therapy is important to prevent these neurological complications and to lower the risk of emboli. Surgical intervention in IE can be safely performed after asymptomatic CNS complications, and may improve survival in selected IE patients without intracranial hemorrhage. However, CNS complications, such as ischemic stroke and brain hemorrhage, were significantly associated with overall mortality. In our study, CNS complications were significant prognostic factors for overall mortality in IE patients.

Various comorbidities have been reported to be associated with mortality in IE patients who undergo surgery. The EuroSCORE II is the best-known predictive model for in-hospital mortality in these patients, and renal impairment, poor mobility, and chronic lung disease are suggested as comorbidities associated with mortality. Other comorbidities, such as the Acute Physiology, Age, Chronic Health Evaluation II score, diabetes mellitus, and Charlson Comorbidity Index, are also reported as major risk factors for in-hospital and 1-year mortality. This trend is also seen in long-term mortality, and several studies have shown that various comorbidities, such as the Charlson Comorbidity Index, renal impairment, and hepatic dysfunction, are associated with mortality in IE patients. We also showed that the Charlson Comorbidity Index was crucial risk factor for overall mortality in IE patients.

Our study has some limitations. First, this was a retrospective study with a relatively small sample size of positive valve cultures. Second, although many variables that can affect treatment were well balanced between valve culture-positive and -negative groups, such as composition of microorganisms, previous IE history, previous valve history, affected valves, comorbidities, vegetations, and duration of antibiotic treatment, age and Charlson Comorbidity Index were not completely balanced. Nevertheless, we attempted to overcome this limitation by considering potential confounders through the Cox regression multivariable analysis. Therefore, further larger prospective studies are warranted. Although the study population differed from that in our study, Munoz discussed the false positivity of valve culture. Whole-genome sequencing or 16S rDNA sequencing may reduce the false positivity and increase diagnostic accuracy. Another strength of our study was the long observation period (median 63 months, IQR 38–104), which improves the reliability of our results regarding the long-term prognosis of IE patients.
CONCLUSION

Positive valve culture was an important factor influencing long-term overall mortality in IE patients who underwent valve surgery. Therefore, it is critical to perform appropriate valve culture during surgery in IE patients. Based on our study, the importance of valve culture positivity needs to be re-evaluated, as the valve culture positivity rate increases with increasing early surgical intervention.

ACKNOWLEDGEMENTS

Funding. This study and the Rapid Service Fee were supported by the National Research Foundation of Korea (NRF) grant funded by the government (MSIT) (No. 2022R1C1C1010012).

Authorship. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Author Contributions. Jinnam Kim, Jung Ho Kim, Hi Jae Lee, Nam Su Ku, Seung Hyun Lee made substantial contributions to study concept and design; data collection; data analysis; data interpretation; drafting of the manuscript; critical revision of the manuscript. All the other authors made substantial contributions to study design, data collection and critical revision of the manuscript for important intellectual content. All authors read and approved the final manuscript.

Disclosures. Jinnam Kim, Jung Ho Kim, Hi Jae Lee, Se Ju Lee, Ki Hyun Lee, Eun Hwa Lee, Yae Jee Baek, Jin Young Ahn, Su Jin Jeong, Nam Su Ku, Seung Hyun Lee, Jun Yong Choi, Joonsup Yeom declare that they have no conflict of interest.

Compliance with Ethics Guidelines. This study was approved by the institutional review boards (IRBs) of Yonsei University College of Medicine (IRB no. 4-2018-0248). Informed consent was waived due to the retrospective nature of the study, which complied with the Good Clinical Practice guidelines and the Declaration of Helsinki.

Data Availability. The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Open Access. This article is licensed under a Creative Commons Attribution-Non-Commercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

REFERENCES

1. Park LP, Chu VH, Peterson G, Skoutelis A, Lejkov-Zupa T, Bouza E, et al. Validated risk score for predicting 6-month mortality in infective endocarditis. J Am Heart Assoc. 2016;5(4): e003016.

2. Mokhles MM, Ciampichetti I, Head SJ, Takkenberg JJ, Bogers AJ. Survival of surgically treated infective endocarditis: a comparison with the general Dutch population. Ann Thorac Surg. 2011;91(5):1407–12.

3. Mylonakis E, Calderwood SB. Infective endocarditis in adults. N Engl J Med. 2001;345(18):1318–30.

4. Wang A, Gaca JG, Chu VH. Management considerations in infective endocarditis: a review. JAMA. 2018;320(1):72–83.
5. Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta JP, Del Zotti F, et al. ESC Guidelines for the management of infective endocarditis: the task force for the management of infective endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J. 2015;36(44):3075–128.

6. Nadji G, Rusinaru D, Rémandi JP, Jeu A, Sorel C, Tribouilloy C. Heart failure in left-sided native valve infective endocarditis: characteristics, prognosis, and results of surgical treatment. Eur J Heart Fail. 2009;11(7):668–75.

7. San Román JA, López J, Vilacosta I, Luaces M, Sarriá C, Revilla A, et al. Prognostic stratification of patients with left-sided endocarditis determined at admission. Am J Med. 2007;120(4):369.e1-7.

8. García-Cabrera E, Fernández-Hidalgo N, Almirante B, Ivanova-Georgieva R, Noureddine M, Plata A, et al. Neurological complications of infective endocarditis: risk factors, outcome, and impact of cardiac surgery: a multicenter observational study. Circulation. 2013;127(23):2272–84.

9. Tornos P, Iung B, Permanyer-Miralda G, Baron G, Delahaye F, Gohlke-Bärwolf C, et al. Infective endocarditis in Europe: lessons from the Euro heart survey. Heart (Brit Card Soc). 2005;91(5):571–5.

10. Kang DH, Kim YJ, Kim SH, Sun BJ, Kim DH, Yun SC, et al. Early surgery versus conventional treatment for infective endocarditis. N Engl J Med. 2012;366(26):2466–73.

11. Murdoch DR, Corey GR, Hoen B, Miró JM, Fowler VG Jr, Bayer AS, et al. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study. Arch Intern Med. 2009;169(5):463–73.

12. García-Granja PE, López J, Vilacosta I, Sarriá C, Ladrón R, Olmos C, et al. Impact of valve culture in the prognosis of active left-sided infective endocarditis. Clin Inf Dis. 2019;68(6):1017–23.

13. Fillatère P, Gacouin A, Revest M, Maamar A, Patrat-Delon S, Flécher E, et al. Determinants and consequences of positive valve culture when cardiac surgery is performed during the acute phase of infective endocarditis. Eur J Clin Microbiol Infect Dis. 2020;39(4):629–35.

14. Arzanauskienė R, Zabiela P, Jonkaitiene R. [Effect of blood and valve cultures on complication rate and outcome of infective endocarditis (analysis of data of patients treated at Kaunas district hospitals, 1999–2001)]. Medicina (Kaunas). 2002;38(10):996–1002.

15. Li JS, Sexton DJ, Mick N, Nettles R, Fowler VG Jr, Ryan T, et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Inf Dis. 2000;30(4):633–8.

16. Brandão TJ, Januario-da-Silva CA, Correia MG, Zappa M, Abrantes JA, Dantas AM, et al. Histopathology of valves in infective endocarditis, diagnostic criteria and treatment considerations. Infection. 2017;45(2):199–207.

17. Gisler V, Dürr S, Irincheieva I, Limacher A, Droz S, Carrel T, et al. Duration of pre-operative antibiotic treatment and culture results in patients with infective endocarditis. J Am Coll Cardiol. 2020;76(1):31–40.

18. Baddour LM, Wilson WR, Bayer AS, Fowler VG Jr, Tleyjeh IM, Rybak MJ, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation. 2015;132(15):1435–86.

19. Morris AJ, Drinkovic D, Potumaryth S, Strickett MG, MacCulloch D, Lambie N, et al. Gram stain, culture, and histopathological examination findings for heart valves removed because of infective endocarditis. Clin Inf Dis. 2003;36(6):697–704.

20. Kim JH, Lee HJ, Ku NS, Lee SH, Lee S, Choi JY, et al. Infective endocarditis at a tertiary care hospital in South Korea. Heart (Brit Card Soc). 2021;107(2):135–41.

21. Rao VP, Wu J, Gillott R, Baig MW, Kaul P, Sandoe JAT. Impact of the duration of antibiotic therapy on relapse and survival following surgery for active infective endocarditis. Eur J Cardio-thorac Surg. 2019;55(4):760–5.

22. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.

23. Nashef SA, Roques F, Sharples LD, Nilsson J, Smith C, Goldstone AR, et al. EuroSCORE II. Eur J Cardio-thorac Surg. 2012;41(4):734–44 (discussion 44–45).

24. Santoshkumar B, Radhakrishnan K, Balakrishnan KG, Sarma PS. Neurologic complications of infective endocarditis observed in a south Indian referral hospital. J Neurol Sci. 1996;137(2):139–44.

25. Fernandez-Felix BM, Barca LV, Garcia-Esquinas E, Correa-Pérez A, Fernández-Hidalgo N, Muriel A, et al. Prognostic models for mortality after cardiac
surgery in patients with infective endocarditis: a systematic review and aggregation of prediction models. Clin Microbiol Inf. 2021;27(10):1422–30.

26. Gatti G, Perrotti A, Obadia JF, Duval X, Jung B, Alla F, et al. Simple scoring system to predict in-hospital mortality after surgery for infective endocarditis. J Am Heart Assoc. 2017;6(7): e004806.

27. Anantha Narayanan M, Mahfood Haddad T, Kalil AC, Kanmanthareddy A, Suri RM, Mansour G, et al. Early versus late surgical intervention or medical management for infective endocarditis: a systematic review and meta-analysis. Heart (Brit Card Soc). 2016;102(12):950–7.

28. Tsao YT, Wang WJ, Lee SW, Hsu JC, Ho FM, Chen WL. Characterization of Staphylococcus lugdunensis endocarditis in patients with cardiac implantable electronic devices. Int J Inf Dis. 2012;16(6):e464–7.

29. Noshak MA, Rezaee MA, Hasani A, Mirzaii M. The role of the coagulase-negative Staphylococci (CoNS) in infective endocarditis; a narrative review from 2000 to 2020. Curr Pharm Biotechnol. 2020;21(12):1140–53.

30. Abramczuk E, Hryniewiecki T, Stepnińska J. Effects of pathogenic factors on prognosis in patients with prosthetic valve endocarditis. Kardiol Pol. 2007;65(2):115–22 (discussion 23–24).

31. Tchana-Sato V, Hans G, Froppiat F, Zehkmini I, Dulgheru R, Lavigne JP, et al. Surgical management of Staphylococcus capitis prosthetic valve infective endocarditis: retrospective review of a 10-year single center experience and review of the literature. J Infect Public Health. 2020;13(11):1705–9.

32. Chu VH, Woods CW, Miro JM, Hoen B, Cabell CH, Pappas PA, et al. Emergence of coagulase-negative staphylococci as a cause of native valve endocarditis. Clin Inf Dis. 2008;46(2):232–42.

33. Habib G, Badano L, Tribouilloy C, Vilacosta I, Zamorano JL, Galderisi M, et al. Recommendations for the practice of echocardiography in infective endocarditis. Eur J Echocardiogr. 2010;11(2):202–19.

34. Delahaye F, Ecochard R, de Gevigney G, Barjhoux C, Malquarti V, Saradarian W, et al. The long term prognosis of infective endocarditis. Eur Heart J. 1995;16(Suppl B):48–53.

35. Tahon J, Geselle PJ, Vandenberk B, Hill EE, Peertmans WE, Herijgers P, et al. Long-term follow-up of patients with infective endocarditis in a tertiary referral center. Int J Cardiol. 2021;331:176–82.

36. Dickerman SA, Abrutyn E, Barsic B, Bouza E, Cecchi E, Moreno A, et al. The relationship between the initiation of antimicrobial therapy and the incidence of stroke in infective endocarditis: an analysis from the ICE Prospective Cohort Study (ICE-PCS). Am Heart J. 2007;154(6):1086–94.

37. Thuny F, Avierinos JF, Tribouilloy C, Giorgi R, Casalta JP, Milandre L, et al. Impact of cerebrovascular complications on mortality and neurologic outcome during infective endocarditis: a prospective multicentre study. Eur Heart J. 2007;28(9):1155–61.

38. Heiro M, Nikoskelainen J, Engblom E, Kotilainen E, Marttila R, Kotilainen P. Neurologic manifestations of infective endocarditis: a 17-year experience in a teaching hospital in Finland. Arch Intern Med. 2000;160(18):2781–7.

39. Chu VH, Cabell CH, Benjamin DK Jr, Kuniholm EF, Fowler VG Jr, Engemann J, et al. Early predictors of in-hospital death in infective endocarditis. Circulation. 2004;109(14):1745–9.

40. Habib G, Erba PA, Jung B, Donal E, Cosyns B, Larocche C, et al. Clinical presentation, aetiology and outcome of infective endocarditis Results of the ESC-EORP EURO-ENDO (European infective endocarditis) registry: a prospective cohort study. Eur Heart J. 2019;40(39):3222–32.

41. Diab M, Sponholz C, Von Loeffelholz C, Scheffel P, Bauer M, Kortgen A, et al. Impact of perioperative liver dysfunction on in-hospital mortality and long-term survival in infective endocarditis patients. Infection. 2017;45(6):857–66.

42. Mirabel M, Sonneville R, Hajage D, Novy E, Tubach F, Vignon P, et al. Long-term outcomes and cardiac surgery in critically ill patients with infective endocarditis. Eur Heart J. 2014;35(18):1195–204.

43. Tischler MD, Vaitkus PT. The ability of vegetation size on echocardiography to predict clinical complications: a meta-analysis. J Am Soc Echocardiogr. 1997;10(5):562–8.

44. Thuny F, Giorgi R, Habachi R, Ansaldi S, Le Dolley Y, Casalta JP, et al. Excess mortality and morbidity in patients surviving infective endocarditis. Am Heart J. 2012;164(1):94–101.

45. Muñoz P, Bouza E, Marín M, Alcalá L, Rodríguez Críexmens M, Valerio M, et al. Heart valves should not be routinely cultured. J Clin Microbiol. 2008;46(9):2897–901.

46. Vondracek M, Sartipy U, Aufwerber E, Julander I, Lindblom D, Westling K. 16S rDNA sequencing of valve tissue improves microbiological diagnosis in surgically treated patients with infective endocarditis. J Infect. 2011;62(6):472–8.